康美药业陷入“财务造假”疑云事件舆情监测报告

 

 　　On April 29,2019,KANGMEI PHARMACEUTICAL CO., LTD,a giant in the Chinese herbal medicine industry,released its 2018 annual report and announced that it would correct the “accounting errors” that appeared in the 2017 annual report.After adjustment, KANGMEI PHARMACEUTICAL CO., LTD has a total of 29.94 billion yuan of monetary funds,operating income of 8.9 billion yuan, operating costs of 7.66 billion yuan,combined cash flow statement sales of goods,labor services received more cash items 10.3 billion yuan,more than 7.3 billion yuan in cash items for goods and services,and 3.82 billion yuan for other cash items related to business activities.The industry believes that KANGMEI PHARMACEUTICAL CO., LTD has financial fraud,and the founder of KANGMEI PHARMACEUTICAL CO., LTD stated in a public apology letter that this was caused by “rapid development resulting in imperfect financial management” and responded to “financial errors” in the interview. "It is different from "financial fraud",but this is not the first time KANGMEI PHARMACEUTICAL CO., LTD has fallen into the "financial fraud" cloud.